Literature DB >> 2536126

Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance.

J W Oosterhuis1, S M Castedo, B de Jong, C J Cornelisse, A Dam, D T Sleijfer, H Schraffordt Koops.   

Abstract

The ploidy of testicular germ cell tumors (GCT), a heterogeneous group of neoplasms, was studied by DNA flow cytometry. The DNA index for infantile yolk sac tumor (N = 10), seminomas (N = 20), and nonseminomas (N = 36), was: 1.91, 1.66, and 1.43, respectively. These values differed significantly one from another (p less than 0.01). The seminoma and nonseminoma components of combined tumors (N = 16) had a significantly different median DNA index of 1.61 and 1.40, respectively. Three of the 10 infantile yolk sac tumors, but only one of the 72 testicular GCT of adults were diploid. The consistent aneuploidy of testicular GCTs of adults might be helpful in the differential diagnosis of primary nongerm cell tumors of the testis, and in differentiating between metastases of testicular GCTs and primary extragonadal malignant GCTs. These data fit into a model of pathogenesis of testicular GCTs of adults in which all tumors, with the possible exception of spermatocytic seminoma, pass through a seminoma stage. Tumor evolution seems to result from net loss of chromosomes from a (near)tetraploid carcinoma in situ cell. The pathogenesis of infantile yolk sac tumor might be different from that of testicular GCTs of adults.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536126

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  32 in total

1.  Bipolar (neural and myoblastic) phenotype in cell lines derived from human germ cell tumours of testis.

Authors:  S Navarro; R Noguera; A Peydró-Olaya; A Llombart-Bosch
Journal:  Virchows Arch       Date:  1997-04       Impact factor: 4.064

2.  X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status.

Authors:  L H Looijenga; A J Gillis; R J van Gurp; A J Verkerk; J W Oosterhuis
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  Differentiation patterns in human testicular germ cell tumours.

Authors:  B Czernobilsky
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Recent developments in the management of germ cell tumors.

Authors:  Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

5.  Carcinoma in situ of the testis. Detection of malignant germ cells in seminal fluid by means of in situ hybridization.

Authors:  A Giwercman; A H Hopman; F C Ramaekers; N E Skakkebaek
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 6.  Testicular germ cell tumor genomics.

Authors:  Solomon L Woldu; James F Amatruda; Aditya Bagrodia
Journal:  Curr Opin Urol       Date:  2017-01       Impact factor: 2.309

7.  Fatty acid synthase overexpression in adult testicular germ cell tumors: potential role in the progression of non-seminomatous germ cell tumors.

Authors:  Kosuke Miyai; Keiichi Iwaya; Tomohiko Asano; Seiichi Tamai; Osamu Matsubara; Hitoshi Tsuda
Journal:  Virchows Arch       Date:  2013-12-14       Impact factor: 4.064

Review 8.  Molecular biology of testicular germ cell tumors: current status.

Authors:  B Schmidt; R Ackermann; T Strohmeyer
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

9.  Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience.

Authors:  Salma K Jabbour; Zhe Zhang; Dagmar Arnold; Moody D Wharam
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

10.  Canine classical seminoma: a specific malignant type with human classifications is highly correlated with tumor angiogenesis.

Authors:  Jong-Hyuk Kim; Chi-Ho Yu; Ji-Young Yhee; Keum-Soon Im; Na-Hyun Kim; Jung-Hyang Sur
Journal:  BMC Cancer       Date:  2010-05-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.